Goldman Sachs’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$74M Buy
888,409
+148,103
+20% +$11.7M 0.01% 1259
2025
Q4
$57.6M Buy
740,306
+28,862
+4% +$1.95M 0.01% 1396
2025
Q3
$40.3M Buy
711,444
+432,708
+155% +$19.5M 0.01% 1610
2025
Q2
$12.2M Sell
278,736
-65,501
-19% -$2.26M ﹤0.01% 2587
2025
Q1
$9.42M Sell
344,237
-89,707
-21% -$3.27M ﹤0.01% 2750
2024
Q4
$17.5M Buy
433,944
+209,113
+93% +$9.44M ﹤0.01% 2266
2024
Q3
$10.6M Sell
224,831
-237,478
-51% -$10.5M ﹤0.01% 2644
2024
Q2
$13.8M Buy
462,309
+11,791
+3% +$408K ﹤0.01% 2196
2024
Q1
$18.1M Sell
450,518
-224,137
-33% -$8.02M ﹤0.01% 1935
2023
Q4
$17.2M Buy
674,655
+469,947
+230% +$8.4M ﹤0.01% 2044
2023
Q3
$2.85M Sell
204,708
-136,837
-40% -$2.75M ﹤0.01% 3478
2023
Q2
$7.85M Buy
341,545
+44,702
+15% +$1.28M ﹤0.01% 2685
2023
Q1
$8.8M Sell
296,843
-41,087
-12% -$1.33M ﹤0.01% 2537
2022
Q4
$8.43M Buy
337,930
+1,171
+0.3% +$31.2K ﹤0.01% 2724
2022
Q3
$7.33M Buy
336,759
+59,495
+21% +$1.57M ﹤0.01% 2800
2022
Q2
$5.46M Buy
277,264
+33,338
+14% +$779K ﹤0.01% 3057
2022
Q1
$10.3M Sell
243,926
-23,864
-9% -$1.01M ﹤0.01% 2664
2021
Q4
$17M Buy
267,790
+87,583
+49% +$5.1M ﹤0.01% 2277
2021
Q3
$10.6M Buy
180,207
+100,204
+125% +$5.81M ﹤0.01% 2671
2021
Q2
$3.88M Buy
80,003
+65,507
+452% +$2.84M ﹤0.01% 3576
2021
Q1
$563K Sell
14,496
-13,434
-48% -$809K ﹤0.01% 5032
2020
Q4
$1.73M Sell
27,930
-119,808
-81% -$5.84M ﹤0.01% 3825
2020
Q3
$4.77M Buy
+147,738
New +$4.51M ﹤0.01% 2942

Other funds holding KYMR